Drug Profile
Dabrafenib-trametinib companion diagnostic - bioMerieux/GSK/Response Genetics
Alternative Names: BRAF V600 theranostic test; THxID-BRAFLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator bioMerieux SA; GlaxoSmithKline
- Developer bioMerieux SA; GSK
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Malignant melanoma
Most Recent Events
- 10 Jun 2014 Launched for Malignant melanoma in USA (unspecified route)
- 29 May 2013 Registered for Malignant melanoma in USA (unspecified route)
- 31 Jul 2012 Preregistration for Malignant melanoma in USA (unspecified route)